Application of kusnezoff monkshood root in preparation of antiepileptic drug and action mechanism analysis method

Through the online pharmacological analysis of Caowu, the network map of Caowu-epileptic "drug active ingredients-key targets-disease-path" was constructed, revealing the anti-epileptic mechanism of Caowu, solving the shortage of existing anti-epileptic drugs and Drug resistance issues provide new treatment options, reducing R&D costs and improving efficiency.

CN118942531AActive Publication Date: 2024-11-12NINGXIA MEDICAL UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410932794.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-12
Estimated Expiration
2044-07-12

AI Technical Summary

Technical Problem

The existing antiepileptic drug treatment methods are short of drugs and high cost pressure, and most patients are resistant to existing drugs and lack the development of new antiepileptic drugs. It is urgent to explore new treatment mechanisms.

Method used

Caowu is used as an anti-epileptic drug, and the active ingredients are screened through the Chinese medicine system pharmacology database and analysis platform, and combined with the disease target database and the KEGG database, the network map of Caowu-epileptic "drug active ingredients-key targets-disease-pathway" is constructed. It is revealed that the active ingredient of Caowu exerts anti-epileptic effects through multi-target, multi-path and multi-path regulation.

Benefits of technology

The new use of Caowu in the preparation of anti-epileptic drugs was discovered. Through network pharmacology and molecular docking technology, the mechanism of action of Caowu in anti-epileptics was revealed, which improved the screening and prediction efficiency of drug active ingredients, narrowed the scope of research and development, and saved Drug development costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention provides application of kusnezoff monkshood root in preparation of anti-epileptic drugs and an action mechanism analysis method, and relates to the technical field of anti-epileptic drugs, starting from chemical structures of active ingredients of the kusnezoff monkshood root, network pharmacology and a molecular docking technology are applied to construct an anti-epileptic'active pharmaceutical ingredient-key target-disease-pathway 'network diagram of the kusnezoff monkshood root; the invention reveals how the active ingredients of the radix aconiti agrestis exert the drug effect through'multi-target, multi-path and multi-path 'combined regulation and control, and predicts the anti-epileptic target and mechanism of the radix aconiti agrestis; the kusnezoff monkshood root provides a certain theoretical reference for research and development of anti-epileptic drugs and functional foods.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of anti-epileptic drugs, and specifically relates to an application of Aconitum kusnezoffii in the preparation of anti-epileptic drugs and a method for analyzing the mechanism of action. Background Art

[0002] Epilepsy is a chronic central nervous system disease characterized by recurrent seizures. It not only seriously affects the daily life of patients, but also the risk of premature death in patients with epilepsy is three times that of the normal population. Due to the sudden repetitive and transient perceptual or behavioral disorders caused by the high synchronization of cortical neuronal networks, individuals experience long-term abnormal discharges in the brain. Due to the high disability rate, long course of the disease, and easy recurrent seizures of epilepsy, long-term medication is required, which imposes a huge economic burden on patients and their families. Therefore, there is an urgent need to find new anti-epileptic drugs in the clinic to solve the current shortage of therapeutic drugs and the high cost pressure, which is of great significance to patients, their families and the entire society. The main treatment for epilepsy is oral drugs, and the development of its drugs is being upgraded. This is because up to one-third of epilepsy patients continue to resist drugs. The focus of treatment development is now on discovering new mechanisms of action. Many traditional Chinese medicines have anti-epileptic effects. At present, the main effective traditional Chinese medicines for the treatment of epilepsy are found to be turmeric, scorpion, calamus, Uncaria rhynchophylla, Ganoderma lucidum, etc. The main compounds that have therapeutic effects on epilepsy are curcumin, gastrodin, ligustrazine, baicalin and rhynchophylline. These Chinese medicines have played an important role in the clinical treatment of epilepsy in traditional Chinese medicine. Now we explore a new Chinese medicine and its new mechanism of action to treat epilepsy. Summary of the invention

[0003] In view of this, the present invention provides a use of Aconitum kusnezoffii in preparing an anti-epileptic drug.

[0004] It is also necessary to provide a method for analyzing the anti-epileptic mechanism of action of Aconitum kusnezoffii.

[0005] The technical solution adopted by the present invention to solve its technical problem is:

[0006] A use of Aconitum kusnezoffii in preparing an anti-epileptic drug.

[0007] Preferably, the active ingredients of Aconitum kusnezoffii are: N-dimethyl-1-phenylmethylamine (BDMA), 2-(3,4-dimethoxyphenyl)-N-methylethylamine (N-Methylhomoveratrylamine), Izoteolin, and palmitic acid.

[0008] Preferably, Aconitum kusnezoffii exerts its anti-epileptic effect by regulating the G-protein coupled receptor molecular signaling pathway of the neuroactive ligand-receptor pathway through the key disease-related targets of CHRM1, ADRA2A, CHRM2, OPRD1, and OPRM1.

[0009] The method for analyzing the anti-epileptic mechanism of action of Aconitum kusnezoffii as described above comprises the following steps:

[0010] S1 Screening of targets of active ingredients of Aconitum kusnezoffii: Screening through the Chinese medicine system pharmacology database and analysis platform to predict the targets of active ingredients of Aconitum kusnezoffii;

[0011] S2 Screening of key targets for the anti-epileptic effect of Aconiti kusnezoffii: The disease target database Disgenet was used for screening to obtain epilepsy disease gene targets, and then the targets of the active ingredients of Aconiti kusnezoffii obtained in S1 were mapped with the epilepsy disease gene targets to obtain the intersection targets of Aconiti kusnezoffii and epilepsy, i.e., the anti-epileptic action targets of Aconiti kusnezoffii; S3 Enrichment analysis of the anti-epileptic pathway of Aconiti kusnezoffii: The anti-epileptic action targets of Aconiti kusnezoffii obtained in S2 were screened through the KEGG database to obtain the number of KEGG pathways, which reflected multiple biological processes in the body, indicating that Aconiti kusnezoffii may exert its anti-epileptic effect by improving these biological processes;

[0012] S4 Drug active ingredient-key target-disease-pathway network construction: The targets of the active ingredients of Aconiti Kusnezoffii obtained in S1, the epilepsy disease gene targets obtained in S2, and the pathways obtained in S3 were used to construct a "drug active ingredient-key target-disease-pathway" network diagram through Cytoscape, which clearly shows the relationship between the drug ingredients and their metabolites and the diseases and their genes as well as the pathways, making it easier to explore the anti-epileptic mechanism of Aconiti Kusnezoffii Kusnezoffii;

[0013] S5 Enrichment analysis of the anti-epileptic target of Aconiti kusnezoffii to explore its mechanism of action: The anti-epileptic target of Aconiti kusnezoffii obtained in S2 was analyzed by GO analysis of cell components, biological processes, and molecular functions, and a protein interaction network was constructed to obtain an in-depth understanding of the anti-epileptic mechanism of Aconiti kusnezoffii;

[0014] S6 Molecular docking of active ingredients of Aconitum kusnezoffii and anti-epileptic targets: The protein receptor in the anti-epileptic target of Aconitum kusnezoffii obtained in S2 is used to collect the crystal structure corresponding to the protein through the RCSB PDB database, and then the protein is pretreated to obtain the protein active site, and then the target of the active ingredient of Aconitum kusnezoffii in the anti-epileptic target of Aconitum kusnezoffii obtained in S2 is pretreated to obtain the pretreated ligand, and the protein active site is molecularly docked with the pretreated ligand to verify the anti-epileptic mechanism of action of Aconitum kusnezoffii.

[0015] Preferably, in the screening of the effective ingredient targets of S1 Aconiti kusnezoffii, the main effective ingredient targets of Aconiti kusnezoffii are predicted by searching the Chinese medicine system pharmacology database and analysis platform TCMSP, and the effective ingredient target proteins are uniformly converted into gene names using the Uniprot database.

[0016] Preferably, in the screening of the key targets of S2 Aconite for anti-epileptic effect, there are 6 targets of Aconite for anti-epileptic effect, namely, muscarinic acetylcholine receptor M1, α-2A adrenergic receptor, muscarinic acetylcholine receptor M2, δ-type opioid receptor, Mu-type opioid receptor, and tumor necrosis factor, and the corresponding active ingredients of Aconite are N-dimethyl-1-phenylmethylamine, 2-(3,4-dimethoxyphenyl)-N-methylethylamine, izoterine, and palmitic acid.

[0017] Preferably, in the S3 Aconite anti-epileptic pathway enrichment analysis, the KEGG pathway includes: neuroactive ligand-receptor interaction, calcium signaling pathway, PI3K-Akt signaling pathway, regulation of actin cytoskeleton, pathway of neurodegenerative multiple diseases, cholinergic synapse, sphingolipid signaling pathway, and cGMP-PKG signaling pathway.

[0018] Preferably, the target enrichment analysis of S5 Aconite for anti-epileptic effect to explore its mechanism of action includes the following analysis:

[0019] GO enrichment analysis: The anti-epileptic targets of Aconiti Kusnezoffii obtained by S2 were screened through the DAVID database, and the screening results were subjected to GO analysis to obtain the signal pathways, cellular components and molecular functions of the biological processes involved in Aconiti Kusnezoffii;

[0020] Construction of PPI network: The anti-epileptic targets of Aconitum kusnezoffii obtained by S2 were imported into the STRING database through venny to construct a protein-protein interaction diagram and obtain the protein genes involved in mutual regulation.

[0021] Preferably, in the construction of the PPI network, the protein genes involved in the mutual regulation are: muscarinic acetylcholine receptor M1, α-2A adrenergic receptor, muscarinic acetylcholine receptor M2, δ-type opioid receptor, Mu-type opioid receptor, and tumor necrosis factor.

[0022] Preferably, the Mu-type opioid receptor engagement is optimal.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] The present invention discovers the application of Aconitum kusnezoffii in the preparation of anti-epileptic drugs, develops new uses of Aconitum kusnezoffii, and also explores a new traditional Chinese medicine for the treatment of epilepsy.

[0025] Starting from the chemical structure of the effective ingredients of Aconitum kusnezoffii, the present invention applies network pharmacology and molecular docking technology to construct a "drug active ingredient-key target-disease-pathway" network diagram of Aconitum kusnezoffii's anti-epileptic effect, reveals how the active ingredients of Aconitum kusnezoffii exert their efficacy through the joint regulation of "multi-target, multi-pathway, and multi-way", and predicts the anti-epileptic targets and mechanisms of Aconitum kusnezoffii; it provides a certain theoretical reference for the research and development of Aconitum kusnezoffii as an anti-epileptic drug and functional food.

[0026] The present invention makes the research method of drug-effect diseases networked and systematized. Compared with the traditional research method, it narrows the research and development scope and makes the research and development purpose precise, thus saving the cost of drug research and development. At the same time, it greatly improves the efficiency of drug active ingredient screening and prediction. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is the Venn diagram of the intersection target of Aconitum kusnezoffii and epilepsy.

[0028] Figure 2 This is a KEGG pathway enrichment analysis diagram.

[0029] Figure 3 This is a network relationship diagram of Aconitum kusnezoffii-active ingredient-target-epilepsy-pathway.

[0030] Figure 4 For G0 enrichment analysis.

[0031] Figure 5 Bubble plot for G0 enrichment analysis.

[0032] Figure 6 This is the target protein interaction network diagram (PPI).

[0033] Figure 7 This is the molecular docking diagram of the active ingredients of Aconitum kusnezoffii and anti-epileptic targets. DETAILED DESCRIPTION

[0034] The technical solutions and technical effects of the embodiments of the present invention are further described in detail below in conjunction with the accompanying drawings of the present invention.

[0035] A use of Aconitum kusnezoffii in preparing an anti-epileptic drug.

[0036] Compared with the prior art, the present invention has the following beneficial effects:

[0037] The present invention discovers the application of Aconitum kusnezoffii in the preparation of anti-epileptic drugs, develops new uses of Aconitum kusnezoffii, and also explores a new traditional Chinese medicine for the treatment of epilepsy.

[0038] Furthermore, the active ingredients of Aconitum kusnezoffii are: BDMA, N-Methylhomoveratrylamine, Izoteolin, and palmitic acid.

[0039] Furthermore, Aconitum kusnezoffii exerts its anti-epileptic effect by regulating the G-protein coupled receptor molecular signaling pathway of the neuroactive ligand-receptor pathway through the key disease-related targets of CHRM1, ADRA2A, CHRM2, OPRD1, and OPRM1.

[0040] Furthermore, the active ingredient of Aconitum kusnezoffii is: Izoteolin.

[0041] The method for analyzing the anti-epileptic mechanism of action of Aconitum kusnezoffii as described above comprises the following steps:

[0042] S1 Screening of targets of active ingredients of Aconitum kusnezoffii: Screening through the Chinese medicine system pharmacology database and analysis platform to predict the targets of active ingredients of Aconitum kusnezoffii;

[0043] S2 Screening of key targets of Aconiti Kusnezoffii for anti-epileptic effect: Screening was performed through the disease target database Disgenet to obtain epilepsy disease gene targets, and then the targets of the active ingredients of Aconiti Kusnezoffii obtained in S1 were intersected and mapped with the epilepsy disease gene targets to obtain the Aconiti Kusnezoffii-epilepsy intersection targets, i.e., the anti-epileptic action targets of Aconiti Kusnezoffii;

[0044] S3 Enrichment analysis of the anti-epileptic pathway of Aconiti kusnezoffii: The anti-epileptic targets of Aconiti kusnezoffii obtained in S2 were screened through the KEGG database to obtain the number of KEGG pathways, which reflected multiple biological processes in the body, indicating that Aconiti kusnezoffii may exert its anti-epileptic effect by improving these biological processes;

[0045] S4 Drug active ingredient-key target-disease-pathway network construction: The targets of the active ingredients of Aconiti Kusnezoffii obtained in S1, the epilepsy disease gene targets obtained in S2, and the pathways obtained in S3 were used to construct a "drug active ingredient-key target-disease-pathway" network diagram through Cytoscape, which clearly shows the relationship between the drug ingredients and their metabolites and the diseases and their genes as well as the pathways, making it easier to explore the anti-epileptic mechanism of Aconiti Kusnezoffii Kusnezoffii;

[0046] S5 Enrichment analysis of the anti-epileptic target of Aconiti kusnezoffii to explore its mechanism of action: The anti-epileptic target of Aconiti kusnezoffii obtained in S2 was analyzed by GO analysis of cell components, biological processes, and molecular functions, and a protein interaction network was constructed to obtain an in-depth understanding of the anti-epileptic mechanism of Aconiti kusnezoffii;

[0047] S6 Molecular docking of active ingredients of Aconitum kusnezoffii and anti-epileptic targets: The protein receptor in the anti-epileptic target of Aconitum kusnezoffii obtained in S2 is used to collect the crystal structure corresponding to the protein through the RCSB PDB database, and then the protein is pretreated to obtain the protein active site, and then the target of the active ingredient of Aconitum kusnezoffii in the anti-epileptic target of Aconitum kusnezoffii obtained in S2 is pretreated to obtain the pretreated ligand, and the protein active site is molecularly docked with the pretreated ligand to verify the anti-epileptic mechanism of action of Aconitum kusnezoffii.

[0048] Specifically, the Chinese herbal medicine Aconiti Kusnezoffii was screened for components through the TCMSP database, and the component protein targets were converted into gene targets using the uniprot database. The gene targets of epilepsy diseases were then screened through the Disgenet database. Thus, the gene targets of Aconiti Kusnezoffii components and the gene targets of epilepsy diseases were used to obtain 6 intersection gene targets through Venny software, and the component list was reversed to obtain 4 active components. At the same time, the intersection targets were converted into KEGG ID numbers through the KEGG database to obtain related pathways. Based on this, the component genes, disease genes, and pathways have been obtained. The Aconiti Kusnezoffii-component-epilepsy-pathway network diagram was drawn according to the Cytoscape software to visualize the anti-epileptic mechanism of Aconiti Kusnezoffii. In order to explore the relevant biological processes, cellular components, molecular functions and other information of these 6 genes, the David database was used for further GO enrichment analysis. At the same time, in order to explore the relationship between the 6 intersection genes, the String database was used to construct a protein interaction network (PPI), and the anti-epileptic mechanism of Aconiti Kusnezoffii was deeply explored, and it was further verified with the constructed Aconiti Kusnezoffii-component-epilepsy-pathway network diagram. In order to further verify whether the 6 disease gene targets explored have any effect on the 4 active ingredient targets, molecular docking was carried out, which showed a good docking effect and verified the specific ingredients and mechanism of action of Aconitum kusnezoffii in anti-epileptic effect.

[0049] Starting from the chemical structure of the effective ingredients of Aconitum kusnezoffii, the present invention applies network pharmacology and molecular docking technology to construct a "drug active ingredient-key target-disease-pathway" network diagram of Aconitum kusnezoffii's anti-epileptic effect, reveals how the active ingredients of Aconitum kusnezoffii exert their efficacy through the joint regulation of "multi-target, multi-pathway, and multi-way", and predicts the anti-epileptic targets and mechanisms of Aconitum kusnezoffii; it provides a certain theoretical reference for the research and development of Aconitum kusnezoffii as an anti-epileptic drug and functional food.

[0050] The present invention makes the research method of drug-effect diseases networked and systematized. Compared with the traditional research method, it narrows the research and development scope and makes the research and development purpose precise, thus saving the cost of drug research and development. At the same time, it greatly improves the efficiency of drug active ingredient screening and prediction.

[0051] Furthermore, in the screening of the active ingredient targets of S1 Aconitum kusnezoffii, the main active ingredient targets of Aconitum kusnezoffii were predicted by searching the Chinese medicine system pharmacology database and analysis platform TCMSP, and the active ingredient target proteins were uniformly converted into gene names using the Uniprot database.

[0052] Furthermore, in the screening of key targets for the anti-epileptic effect of S2 Aconitum, there are 6 targets for the anti-epileptic effect of Aconitum, namely, muscarinic acetylcholine receptor M1, α-2A adrenergic receptor, muscarinic acetylcholine receptor M2, δ-opioid receptor, Mu-opioid receptor, and tumor necrosis factor, and the corresponding active ingredients of Aconitum are N-dimethyl-1-phenylmethylamine, 2-(3,4-dimethoxyphenyl)-N-methylethylamine, izoterine, and palmitic acid.

[0053] Furthermore, in the S3 Aconite anti-epileptic pathway enrichment analysis, the KEGG pathways include: neuroactive ligand-receptor interaction, calcium signaling pathway, PI3K-Akt signaling pathway, regulation of actin cytoskeleton, pathways of neurodegenerative multiple diseases, cholinergic synapses, sphingolipid signaling pathways, and cGMP-PKG signaling pathways.

[0054] Furthermore, the target enrichment analysis of S5 Aconite for anti-epileptic effect to explore its mechanism of action includes the following analysis:

[0055] GO enrichment analysis: The anti-epileptic targets of Aconiti Kusnezoffii obtained by S2 were screened through the DAVID database, and the screening results were subjected to GO analysis to obtain the signal pathways, cellular components and molecular functions of the biological processes involved in Aconiti Kusnezoffii;

[0056] Construction of PPI network: The anti-epileptic targets of Aconitum kusnezoffii obtained by S2 were imported into the STRING database through venny to construct a protein-protein interaction diagram and obtain the protein genes involved in mutual regulation;

[0057] Furthermore, in the construction of the PPI network, the protein genes involved in the mutual regulation are: muscarinic acetylcholine receptor M1, α-2A adrenergic receptor, muscarinic acetylcholine receptor M2, δ-type opioid receptor, Mu-type opioid receptor, and tumor necrosis factor.

[0058] Furthermore, the Mu-type opioid receptor has the best engagement.

[0059] Furthermore, the molecular docking of the active ingredients of S6 Aconitum and anti-epileptic targets is as follows: the crystal structures corresponding to the six relevant proteins are collected through the RCSB PDB database. The collected protein crystals are pre-processed by the following operations through the Protein Preparation Wizard module of Schrödinger software, namely: ① protein preprocess; ② regenerate states of native ligand; ③ H-bond assignment optimization; ④ protein energy minimization; ⑤ remove waters. Then pre-process the ligand: pre-process the 2Dsdf structure files of the four compounds through the LigPrep module in Schrödinger and generate all their 3D chiral conformations at the same time. Then identify the active site: first use Schrödinger's SiteMap module to predict the best binding site, and then use the ReceptorGrid Generation module in Schrödinger to formulate the best Enclosing box and perfectly wrap the predicted binding site, so as to obtain the active sites of the six proteins. Then the molecules are docked. The 4 processed ligand compounds were respectively docked with the active sites of 6 proteins (using the highest precision XP docking). The lower the score, the lower the free energy of binding between the compound and the protein, and the more stable the binding. Finally, MM-GBSA analysis. By using MM-GBSA to calculate and analyze the active sites of 4 ligand compounds and 6 proteins, MM-GBSAdG Bind can approximately represent the free energy of binding between proteins and small molecules. The lower the binding free energy, the more stable the binding between the ligand compound and the protein.

[0060] For ease of understanding, the present invention is further illustrated by the following examples:

[0061] Embodiment 1:

[0062] S1 Screening of active ingredient targets of Aconitum flavum Hand.-Mazz.: Search the TCMSP database and analysis platform for traditional Chinese medicine system pharmacology with the keyword "Aconitum flavum Hand.-Mazz.", and use drug likeness (DL) ≥ 0.02 and oral bioavailability (OB) ≥ 18% as screening conditions to predict the main active ingredient targets of Aconitum flavum. The ingredient targets were entered into the Uniprot database (https: / / www.uniprot.org / ) with the screening condition of Human, and the active ingredient targets were uniformly converted into gene names; 51 chemical components of Aconitum flavum were obtained as shown in Table 1:

[0063] Table 1

[0064]

[0065]

[0066] S2 Screening of key targets of Aconiti Kusnezoffii for anti-epileptic effect: Disgenet disease gene retrieval platform (https: / / www.disgenet.org / home / ) was used to search for epilepsy-related target genes with the keyword "Epilepsy" and the screening condition of score value "Score">0.3, and a total of 114 disease targets related to epilepsy were obtained as shown in Table 2. The venny2.1.0 online platform (URL: https: / / bioinfogp.cnb.csic.es / tools / venny) was used to import the target of Aconiti Kusnezoffii and the target of epilepsy into the software for intersection, and 6 interactive targets were obtained, as shown in Table 3, Figure 1 As shown, namely Muscarinic acetylcholine receptor M1 (Muscarinic acetylcholine receptor M1, CHRM1), Alpha-2Aadrenergic receptor (Alpha-2Aadrenergic receptor, ADRA2A), Muscarinic acetylcholine receptor M2 (Muscarinic acetylcholinereceptor M2, CHRM2), Delta-type opioid receptor (Delta-type opioid receptor, OPRD1), Mu-type opioid receptor (Mu-type opioid receptor, OPRM1), Tumor necrosis factor (Tumor necrosis factor, TNF) ( Figure 1 ), among which CHRM1, ADRA2A, CHRM2, OPRD1, and OPRM1 all belong to G-protein coupled receptors, and the corresponding active ingredients are N-dimethyl-1-phenylmethylamine (BDMA), 2-(3,4-dimethoxyphenyl)-N-methylethylamine (N-Methylhomoveratrylamine), Izoteolin, and palmitic acid. Among them, BDMA is an active ingredient with an ID number of MOL004753, 2-(3,4-dimethoxyphenyl)-N-methylethylamine (N-Methylhomoveratrylamine) is a metabolite of MOL004754, Izoteolin is a metabolite of MOL004763, and palmitic acid is a metabolite of MOL000069 (Table 3).

[0067] Table 2

[0068]

[0069]

[0070] Table 3

[0071]

[0072] S3 Anti-epileptic pathway enrichment analysis of Aconiti kusnezoffii: The six intersection targets collected from Aconiti kusnezoffii-epileptic diseases were imported into the KEGG database through the venny2.1.0 online platform, the website is https: / / www.kegg.jp / kegg / pathway.html, and KEGGMAPPER multi-point connection was performed. After screening with P < 0.01, a total of 76 KEGG pathway entries were obtained. The top-ranked pathways include: neuroactive ligand-receptor interaction, calcium signaling pathway, PI3K-Akt signaling pathway, regulation of actin cytoskeleton, pathways of neurodegenerative multiple diseases, cholinergic synapses, sphingolipid signaling pathways, and cGMP-PKG signaling pathways, which reflect multiple biological processes in the body and indicate that Aconiti kusnezoffii may exert its anti-epileptic effect by improving these biological processes, such as Figure 2 shown.

[0073] S4 Drug active ingredient-key target-disease-pathway network construction: The active targets of the ingredients of Aconitum kusnezoffii and the targets and pathways of epilepsy diseases were imported into Cytoscape3.7.1 software to construct a network interaction relationship diagram, such as Figure 3 As shown. The picture can intuitively show the relationship between the active ingredients of Aconiti Kusnezoffii and epilepsy targets. The yellow inverted triangle in the center on the left represents epilepsy, the two circles in the center are epilepsy gene targets (green circles), the red circle in the center represents the active ingredients of Aconiti Kusnezoffii (red diamonds), the purple diamonds represent metabolites, and the blue circles on the right represent related pathways (blue triangles). Each edge represents the interaction relationship between target-disease, drug-effective compound, and effective compound-target;

[0074] S5 Target enrichment analysis of Aconite's anti-epileptic effect to explore its mechanism of action:

[0075] GO enrichment analysis: The Aconiti Kusnezoffii-epilepsy intersection targets obtained by Venny2.1.0 were imported into the DAVID6.8 database (https: / / david.ncifcrf.gov) and the system was screened according to P < 0.01. Statistically, 29 BP entries, 17 CC entries, and 7 MF entries were obtained, such as Figure 4As shown in the figure, the GO analysis results show that the biological processes involved in Aconitum kusnezoffii mainly include: G protein-coupled receptor signaling pathway, denylate cyclase inhibition of G protein-coupled acetylcholine receptor signaling pathway, G protein-coupled receptor signaling pathway, opioid receptor signaling pathway, phospholipase C activation of G protein-coupled acetylcholine receptor signaling pathway. Its cellular components mainly include: components of the presynaptic membrane, axon terminals, components of the plasma membrane, presynaptic membrane, components of the postsynaptic density membrane; molecular functions are mainly g protein-coupled acetylcholine receptors, opioid receptor active protein-coupled serotonin receptors, neuropeptide binding, g protein-coupled receptors, such as Figure 5 shown.

[0076] Construction of PPI network: The six intersection targets collected from Aconitum kusnezoffii-epilepsy were imported into the STRING database through the venny2.1.0 online platform, https: / / string-db.org / cgi / input.pl database, the species was set to Homosapiens, and the protein-protein interaction relationship diagram was constructed, as shown in Figure 6 As shown. The results showed that protein kinase OPRM1 was highly involved. In addition, CHRM2, CHRM1, ADRA2A, OPRD1, TNF, etc. were also involved in mutual regulation;

[0077] S6 Molecular docking of active ingredients of Aconiti Kusnezoffii and anti-epileptic targets: The active ingredients of Aconiti Kusnezoffii, BDMA, N-Methylhomoveratrylamine, Izoteolin, palmitic acid, were selected for molecular docking with the key targets for epilepsy treatment, CHRM1, ADRA2A, CHRM2, OPRD1, OPRM1, and TNF. The XP docking results were based on the XP G score reference value. When the value was less than -6, it indicated that the protein and the ligand had stable binding performance. The MM-GBSA analysis results were based on MM-GBSAdG Bind. When it was less than -30 kcal / mol, it indicated that the binding free energy was low and the protein and ligand were stable. Comprehensive analysis of XP docking and MM-GBSA results showed that the docking score of N-Methylhomoveratrylamine and TNF was -3.651, and the MM-GBSA result was -31.22 kcal / mol. The binding free energy was low and the docking score was low, indicating that the compound was more stable in binding with TNF. Izoteolin has the best docking performance with CHRM2, with a docking score of -4.802 and a MM-GBSA result of -36.40 kcal / mol. The binding free energy is low and the docking score is low, indicating that Izoteolin binds to CHRM2 stably. The docking score of Izoteolin with OPRM1 is -5.955 and the MM-GBSA results are -38.82 kcal / mol, respectively. The binding free energy is low and the docking score is low, indicating that the compound binds to OPRM1 stably. The docking score of Izoteolin with ADRA2A is -8.602 and the MM-GBSA result is -49.65 kcal / mol. Both the binding free energy and the docking score are low, indicating that the compound binds to ADRA2A stably. BDMA has the best docking performance with CHRM1, with a docking score of -10.786 and a MM-GBSA result of -33.73 kcal / mol. The binding free energy is low and the docking score is very low, indicating that BDMA binds to CHRM1 very stably). The docking score of izoteolin and OPRD1 is -6.060, and the MM-GBSA result is -45.36 kcal / mol. Both the docking score and the binding free energy are low, indicating that the binding of izoteolin and OPRD1 is stable. Figure 7 shown.

[0078] The mutual verification of the above-mentioned disease network architecture and molecular docking shows that Aconitum kusnezoffii can be used to treat epilepsy. Aconitum kusnezoffii exerts its anti-epileptic effect by regulating the G-protein coupled receptor molecular signaling pathway of the neuroactive ligand-receptor pathway through the key disease-related targets of CHRM1, ADRA2A, CHRM2, OPRD1, OPRM1, and TNF.

[0079] What is disclosed above is only a preferred embodiment of the present invention, which certainly cannot be used to limit the scope of rights of the present invention. A person skilled in the art can understand that all or part of the processes of the above embodiments and equivalent changes made according to the claims of the present invention still fall within the scope of the invention.

Claims

1. An application of Radix Aconiti Kusnezoffii in preparing anti-epileptic drugs.

2. The use of Aconitum kusnezoffii in the preparation of anti-epileptic drugs according to claim 1, characterized in that: The active ingredients of Aconitum kusnezoffii are: BDMA, N-Methylhomoveratrylamine, Izoteolin, and palmitic acid.

3. The use of Aconitum kusnezoffii in the preparation of anti-epileptic drugs according to claim 1, characterized in that: Aconitum kusnezoffii exerts its anti-epileptic effect by regulating the G-protein coupled receptor molecular signaling pathway of the neuroactive ligand-receptor pathway through the key disease-related targets of CHRM1, ADRA2A, CHRM2, OPRD1, and OPRM1.

4. The method for analyzing the anti-epileptic mechanism of action of Aconiti Kusnezoffii according to claim 1, characterized in that: The following steps are involved: S1 Screening of targets of active ingredients of Aconitum kusnezoffii: Screening through the Chinese medicine system pharmacology database and analysis platform to predict the targets of active ingredients of Aconitum kusnezoffii; S2 Screening of key targets of Aconiti Kusnezoffii for anti-epileptic effect: Screening was performed through the disease target database Disgenet to obtain epilepsy disease gene targets, and then the targets of the active ingredients of Aconiti Kusnezoffii obtained in S1 were intersected and mapped with the epilepsy disease gene targets to obtain the Aconiti Kusnezoffii-epilepsy intersection targets, i.e., the anti-epileptic action targets of Aconiti Kusnezoffii; S3 Enrichment analysis of the anti-epileptic pathway of Aconiti kusnezoffii: The anti-epileptic targets of Aconiti kusnezoffii obtained in S2 were screened through the KEGG database to obtain the number of KEGG pathways, which reflected multiple biological processes in the body, indicating that Aconiti kusnezoffii may exert its anti-epileptic effect by improving these biological processes; S4 Drug active ingredient-key target-disease-pathway network construction: The targets of the active ingredients of Aconiti Kusnezoffii obtained in S1, the epilepsy disease gene targets obtained in S2, and the pathways obtained in S3 were used to construct a "drug active ingredient-key target-disease-pathway" network diagram through Cytoscape, which clearly shows the relationship between the drug ingredients and their metabolites and the diseases and their genes as well as the pathways, making it easier to explore the anti-epileptic mechanism of Aconiti Kusnezoffii Kusnezoffii; S5 Enrichment analysis of the anti-epileptic target of Aconiti kusnezoffii to explore its mechanism of action: The anti-epileptic targets of Aconiti kusnezoffii obtained in S2 were analyzed by GO analysis of cell components, biological processes, and molecular functions, and a protein interaction network was constructed to obtain an in-depth understanding of the anti-epileptic mechanism of Aconiti kusnezoffii; S6 Molecular docking of active ingredients of Aconitum kusnezoffii and anti-epileptic targets: The protein receptor in the anti-epileptic target of Aconitum kusnezoffii obtained in S2 is used to collect the crystal structure corresponding to the protein through the RCSB PDB database, and then the protein is pretreated to obtain the protein active site, and then the target of the active ingredient of Aconitum kusnezoffii in the anti-epileptic target of Aconitum kusnezoffii obtained in S2 is pretreated to obtain the pretreated ligand, and the protein active site is molecularly docked with the pretreated ligand to verify the anti-epileptic mechanism of action of Aconitum kusnezoffii.

5. The use of Aconitum kusnezoffii in the preparation of anti-epileptic drugs and the method for analyzing the mechanism of action as claimed in claim 4, characterized in that: In the screening of the active ingredient targets of S1 Aconiti kusnezoffii, the main active ingredient targets of Aconiti kusnezoffii were predicted by searching the traditional Chinese medicine system pharmacology database and analysis platform TCMSP, and the active ingredient target proteins were uniformly converted into gene names using the Uniprot database.

6. The use of Aconitum kusnezoffii in preparing anti-epileptic drugs and the method for analyzing the mechanism of action as claimed in claim 4, characterized in that: In the screening of key targets for the S2 Aconite anti-epileptic effect, there are 6 targets for the anti-epileptic effect of Aconite, namely, muscarinic acetylcholine receptor M1, α-2A adrenergic receptor, muscarinic acetylcholine receptor M2, δ-opioid receptor, Mu-opioid receptor, and tumor necrosis factor. The corresponding active ingredients of Aconite are N-dimethyl-1-phenylmethylamine, 2-(3,4-dimethoxyphenyl)-N-methylethylamine, izoterine, and palmitic acid.

7. The use of Aconitum kusnezoffii in preparing anti-epileptic drugs and the method for analyzing the mechanism of action as claimed in claim 4, characterized in that: In the S3 Aconite anti-epileptic pathway enrichment analysis, the KEGG pathways include: neuroactive ligand-receptor interaction, calcium signaling pathway, PI3K-Akt signaling pathway, regulation of actin cytoskeleton, pathways of neurodegenerative multiple diseases, cholinergic synapses, sphingolipid signaling pathways, and cGMP-PKG signaling pathways.

8. The use of Aconitum kusnezoffii in preparing anti-epileptic drugs and the method for analyzing the mechanism of action as claimed in claim 4, characterized in that: The target enrichment analysis of S5 Aconitum carmichaelii anti-epileptic action includes the following analysis in exploring the mechanism of action: GO enrichment analysis: The anti-epileptic targets of Aconiti Kusnezoffii obtained by S2 were screened through the DAVID database, and the screening results were subjected to GO analysis to obtain the signal pathways, cellular components and molecular functions of the biological processes involved in Aconiti Kusnezoffii; Construction of PPI network: The anti-epileptic targets of Aconitum kusnezoffii obtained by S2 were imported into the STRING database through venny to construct a protein-protein interaction diagram and obtain the protein genes involved in mutual regulation.

9. The use of Aconitum kusnezoffii in preparing anti-epileptic drugs and the method for analyzing the mechanism of action as claimed in claim 8, characterized in that: In the construction of the PPI network, the protein genes involved in mutual regulation are: muscarinic acetylcholine receptor M1, α-2A adrenergic receptor, muscarinic acetylcholine receptor M2, delta opioid receptor, Mu opioid receptor, and tumor necrosis factor.

10. The use of Aconitum kusnezoffii in preparing anti-epileptic drugs and the method for analyzing the mechanism of action according to claim 9, characterized in that: The Mu opioid receptor is best engaged.

Citation Information

Patent Citations

  • Traditional Chinese medicine preparation for treating epilepsy

    CN102119987A

  • Traditional Chinese medicine preparation for treating primary epilepsy and preparation methods

    CN104189456A

  • Preparation for treating madness and preparation method

    CN105126029A

  • Compositions and methods for treating neurological disorders

    CN108348528A

  • Traditional Chinese medicine for treating epilepsy

    CN1094619A